Pfs230D1M-EPA/AS01 Vaccine, a Transmission Blocking Vaccine Against Plasmodium Falciparum, in an Age De-Escalation Trial of Children and a Family Compound Trial in Mali
Study Details
Study Description
Brief Summary
Background:
Malaria affects many people in Mali and other parts of Africa. It is spread by mosquito bites. Malaria can make people sick or can lead to death. Scientists want to learn if a vaccine can stop it from spreading to other people.
Objective:
To test how well an experimental malaria vaccine works to decrease malaria infections.
Eligibility:
Healthy people ages 5 and older who live in Doneguebougou, Mali, and surrounding areas
Design:
Participants will be screened with:
Medical history
Physical exam
Blood, urine, and heart tests
EKG
Participants will be randomly assigned to get either the experimental vaccine or an approved vaccine. They will not know which they are getting.
Participants will have a visit about a week before their first vaccine. They will take a medicine that kills malaria. They will take it at the clinic the next 2 days. Participants ages 5-8 will take the drug again 2 weeks before their third vaccine.
Participants get the vaccine through a needle in the arm. They will have visits 1, 3, 7, and 14 days after. They will have blood tests or finger pricks.
Participants will get another vaccine 1 and 6 months later.
Participants will have blood tests once a month. At these visits they may also have urines tests or mosquito feeds. For the feeds a cup full of mosquitoes will be placed on arms or legs for 15-20 minutes.
Participants will have visits twice a month for 4 months after their last vaccine.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
A vaccine to interrupt malaria transmission (VIMT), targeting disruption of both human and mosquito transmission, would be a valuable tool for local elimination or eradication of this disease. One strategy to design a VIMT is using components that block transmission of malaria to mosquitoes, such as Pfs230. Pfs230, a surface antigen of intracellular gametocytes, as well as extracellular gametes and zygotes in the mosquito stage of Plasmodium falciparum, is currently the leading candidate in clinical trials for a malaria transmission-blocking vaccine (TBV). Recombinant Pfs230D1M has been conjugated to a recombinant Pseudomonas aeruginosa ExoProtein A (EPA) and adjuvanted with AS01. When formulated in AS01, results from a recent first-in-human trial demonstrated that Pfs230-EPA induces functional transmission-reducing, and in a significant proportion of vaccinees, transmission-blocking serum activity that can be measured for months, the vaccine is well-tolerated and safe in adults, and our recent natural history data clearly indicate that children play a disproportionate role in malaria transmission. The next step in the development of Pfs230D1M-EPA as a TBV is therefore to conduct an age de-escalation trial to ensure that the vaccine is safe to administer to children and then to conduct a community clinical trial to assess efficacy in family groups.
This Phase 2 study will first determine safety and tolerability of Pfs230D1M-EPA/AS01 in healthy Malian children of decreasing ages: 9-18 years old, followed by 5-8 years old. A total of 60 subjects will be enrolled in Doneguebougou, Mali, West Africa. Children will be recruited from compounds/family that have agreed to participate in the main phase of the study and will enroll in a staggered manner to receive either Pfs230D1M-EPA/AS01 vaccine or comparator as assigned by their compound block randomization. Prior to receipt of vaccination #1, all subjects will receive a full treatment course of artemether/lumefantrine (AL). Safety and tolerability will be monitored and reported as local and systemic adverse events (AEs) and serious adverse events (SAEs) and reviewed by DSMB, sponsor, medical monitors, and study team prior to proceeding with enrollment of the main phase.
If there are no safety concerns, in a staggered manner, the main phase will begin enrollment of approximately 137 compounds/vaccine units (about 1500 vaccinees + about 400 under 5 years of age for parasite surveillance). Children enrolled during the pilot safety phase will join their main phase compounds/family for vaccination #3. Prior to receipt of first vaccination, all subjects will receive a full treatment course of AL. All vaccinated subjects will be monitored for safety and tolerability. Immunogenicity outcomes will be antibody responses as measured by enzyme-linked immunosorbent assay (ELISA) against recombinant Pfs230D1M. Functional activity of the induced antibodies will be assessed by standard membrane feeding assays in select samples. Vaccine activity will be measured in children 9-18 years of age who will undergo direct skin feeds (DSF) starting 2 weeks post vaccination #3 for a total of 8 DSFs.
Prior to scheduled last vaccination in members of the compound/family, children 1-4 years of age and vaccinated children 5-8 years of age will receive a full treatment course of AL prior to the expected start of the transmission season and will then be followed every 2 weeks by blood smear (BS) along with all vaccinated children. Children 9-18 years of age will also be assessed for vaccine efficacy, but as a separate analysis from those 1-8 years of age.
In Year 2, those who received vaccination during Year 1 (5 years of age and older at enrollment), if eligible and still on study, will receive a single fourth vaccination per their vaccine unit (VU) blinded arm assignment. No new individuals will be enrolled. Again, children 1-4 years of age and vaccinated children 5-8 years of age will receive a full treatment course of AL prior to the expected start of the transmission season and will then be followed every 2 weeks by BS along with all vaccinated children. Children 9-18 years of age will also be assessed for vaccine efficacy against parasitemia, but as a separate analysis from those 1-8 years of age. Immunogenicity outcomes will be antibody responses as measured by ELISA against recombinant Pfs230D1M. Functional activity of the induced antibodies will be assessed by standard membrane feeding assays in select samples. Vaccine activity will be measured in children 9-18 years of age who will undergo DSF starting 2 weeks post vaccination #4 for a total of 10 DSFs.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Arm 1a/3c Arm 1a (pilot) + Arm 3c (main) to receive 40ug of Pfs230D1M-EPA/AS01 on days 0, 28, 168; receipt of artemether/lumefantrine (AL) on day -7 |
Biological: Pfs230D1M-EPA/AS01
The Pfs230D1M-EPA was formulated as conjugated Pfs230D1M in 4 mM phosphate-buffered saline (PBS) to a 2X dilution of the high dose (160 (Micro)g/mL in 0.5 mL volume) in cGMP compliance at Walter Reed Bioproduction facility in April 2016 and will be provided as a single use vial. AS01B adjuvant was manufactured for use in the SHINGRIX vaccine by GSK
Biological: AVAXIM
AVAXIM - Pediatric [Hepatitis A Vaccine Inactivated] is a sterile, whitish, cloudy suspension. The active ingredient is a purified and formaldehyde-inactivated hepatitis A virus (HAV) obtained from the GBM strain, cultured on MRC-5 human diploid cells. HAV is adsorbed onto aluminum.
|
| Active Comparator: Arm 1b/3d Arm 1b (pilot) + Arm 3d (main) to receive HAVRIX (day 0), TYPHIM Vi (day 28), HAVRIX (day 168); receipt of AL on day -7 |
Biological: HAVRIX
HAVRIX (Hepatitis A Vaccine; HAV) is produced by GSK and is a sterile suspension of inactivated virus for IM administration. The virus (strain HM175) is propagated in MRC-5 human diploid cells. HAVRIX is FDA approved for active immunization against disease caused by HAV for persons 12 months of age and older.
Biological: Menactra
Menactra (Sanofi Pasteur) is a sterile, intramuscularly administered vaccine that contains Neisseria meningitidis serogroup A, C, Y, and W-135 capsular polysaccharide antigens individually conjugated to diphtheria toxoid protein. No preservative or adjuvant is added during the manufacturing process. Menactra is FDA approved for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 (but does not protect against serotype B) for use in individuals 9 months through 55 years of age.
|
| Experimental: Arm 2a/3a Arm 2a (pilot) + Arm 3a (main) to receive 40ug of Pfs230D1M-EPA/AS01 on days 0, 28, 168; receipt of AL on day -7 and 154 |
Biological: Pfs230D1M-EPA/AS01
The Pfs230D1M-EPA was formulated as conjugated Pfs230D1M in 4 mM phosphate-buffered saline (PBS) to a 2X dilution of the high dose (160 (Micro)g/mL in 0.5 mL volume) in cGMP compliance at Walter Reed Bioproduction facility in April 2016 and will be provided as a single use vial. AS01B adjuvant was manufactured for use in the SHINGRIX vaccine by GSK
|
| Active Comparator: Arm 2b/3b Arm 2b (pilot) + Arm 3b (main) to receive HAVRIX (day 0), TYPHIM Vi (day 28), HAVRIX (day 168); receipt of AL on day -7 and 154 |
Biological: HAVRIX
HAVRIX (Hepatitis A Vaccine; HAV) is produced by GSK and is a sterile suspension of inactivated virus for IM administration. The virus (strain HM175) is propagated in MRC-5 human diploid cells. HAVRIX is FDA approved for active immunization against disease caused by HAV for persons 12 months of age and older.
Biological: Menactra
Menactra (Sanofi Pasteur) is a sterile, intramuscularly administered vaccine that contains Neisseria meningitidis serogroup A, C, Y, and W-135 capsular polysaccharide antigens individually conjugated to diphtheria toxoid protein. No preservative or adjuvant is added during the manufacturing process. Menactra is FDA approved for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 (but does not protect against serotype B) for use in individuals 9 months through 55 years of age.
|
| Experimental: Arm 3e Arm 3e (main) to receive 40microg of Pfs230D1M-EPA/AS01 on days 0, 28, 168; receipt of AL on day -7 |
Biological: Pfs230D1M-EPA/AS01
The Pfs230D1M-EPA was formulated as conjugated Pfs230D1M in 4 mM phosphate-buffered saline (PBS) to a 2X dilution of the high dose (160 (Micro)g/mL in 0.5 mL volume) in cGMP compliance at Walter Reed Bioproduction facility in April 2016 and will be provided as a single use vial. AS01B adjuvant was manufactured for use in the SHINGRIX vaccine by GSK
|
| Active Comparator: Arm 3f Arm 3f (main) to receive HAVRIX (day 0), TYPHIM Vi (day 28), HAVRIX (day 168); receipt of AL on day -7 |
Biological: HAVRIX
HAVRIX (Hepatitis A Vaccine; HAV) is produced by GSK and is a sterile suspension of inactivated virus for IM administration. The virus (strain HM175) is propagated in MRC-5 human diploid cells. HAVRIX is FDA approved for active immunization against disease caused by HAV for persons 12 months of age and older.
Biological: TYPHIM Vi (Salmonella typhi vaccine)
TYPHIM Vi (Typhoid Vi Polysaccharide Vaccine), produced by Sanofi Pasteur SA, for IM use, is a sterile solution containing the cell surface Vi polysaccharide extracted from Salmonella enterica serovar Typhi, S typhi Ty2 strain (inactivated, subunit vaccine). TYPHIM Vi vaccine is indicated for active immunization for the prevention of typhoid fever caused by S typhi and is FDA approved for use in persons 2 years of age or older
Biological: Menactra
Menactra (Sanofi Pasteur) is a sterile, intramuscularly administered vaccine that contains Neisseria meningitidis serogroup A, C, Y, and W-135 capsular polysaccharide antigens individually conjugated to diphtheria toxoid protein. No preservative or adjuvant is added during the manufacturing process. Menactra is FDA approved for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 (but does not protect against serotype B) for use in individuals 9 months through 55 years of age.
|
| No Intervention: Arm 4a Receipt of AL on day 154 |
|
| No Intervention: Arm 4b Receipt of AL on day 154 |
Outcome Measures
Primary Outcome Measures
- Number of Participants With Local and Systemic Adverse Events in Years 1 and 2 [Within 7 days after each vaccination]
Number of participants with local and systemic adverse events (AEs) graded by severity occurring within 7 days after each vaccine
Eligibility Criteria
Criteria
- INCLUSION CRITERIA FOR GROUPS 1,2,3:
All of the following criteria must be fulfilled for a volunteer to participate in this trial:
-
Meets age requirements for Arm currently being enrolled.
-
Available for the duration of the trial.
-
Family compound known resident or long-term resident (more than 1 year) of Doneguebougou, Mali or surrounding villages.
-
Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process.
-
In good general health and without clinically significant medical history in the opinion of the investigator.
-
Females of childbearing potential must be willing to use reliable contraception from 21 days prior to Study Day 0 and until 1 month after the last vaccination.
- A reliable method of birth control includes one of the following:
-
Confirmed pharmacologic contraceptives (parenteral) delivery;
-
Intrauterine or implantable device
EXCEPTIONS to required pregnancy prevention includes the following:
-
Postmenopausal state: defined as no menses for 12 months without an alternative medical cause
-
Surgical sterilization
-
Unmarried AND not sexually active AND menstruating OR not menstruating females 12-17 years of age
-
NOTE: if a female of childbearing potential s status changes during the course of vaccination through 1 month post vaccination (e.g. they become >=18 years of age, married, or sexually active), the female will be required to start reliable contraception
-
Willing to have blood samples stored for future research.
INCLUSION CRITERIA FOR GROUP 4:
All of the following criteria must be fulfilled for a volunteer to participate in this trial:
-
Meets age requirements for Arm currently being enrolled.
-
Available for the duration of the trial.
-
Family compound known resident or long-term resident (more than 1 year) of Doneguebougou, Mali or surrounding villages.
-
Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process.
-
In good general health and without clinically significant medical history in the opinion of the investigator.
-
Willing to have blood samples stored for future research.
Inclusion Criteria for Groups 1, 2, 3, (Year 2)
All of the following criteria must be fulfilled for a volunteer to continue to participate in this trial:
-
Previously enrolled in the study and has received at least 1 vaccination. 2. Available for the duration of the trial.
-
In good general health and without clinically significant medical history in the opinion of the investigator.
-
Females of childbearing potential must be willing to use reliable contraception from 21 days prior to scheduled vaccine dose #4 and until 1 month after the 4th vaccination.
-A reliable method of birth control includes one of the following:
-
Confirmed pharmacologic contraceptives (parenteral) delivery;
-
Intrauterine or implantable device
EXCEPTIONS to required pregnancy prevention includes the following:
-
Postmenopausal state: defined as no menses for 12 months without an alternative medical cause
-
Surgical sterilization
-
Unmarried AND not sexually active AND menstruatingOR not menstruating females 12-17 years of age
-
NOTE: if a female of childbearing potential s status changes during the course of vaccination through 1 month post vaccination (e.g. they become greater than or equal to 18 years of age, married, or sexually active), the female will be required to start reliable contraception
-
Willing to have blood samples stored for future research.
Inclusion Criteria for Group 4 (Year 2):
All of the following criteria must be fulfilled for a volunteer to continue to participate in this trial:
-
Previously enrolled in the study
-
Available for the duration of the trial.
-
In good general health and without clinically significant medical history in the opinion of the investigator.
-
Willing to have blood samples stored for future research.
EXCLUSION CRITERIA FOR GROUPS 1, 2, 3:
An individual will be excluded from participating in this trial if any one of the following criteria is fulfilled:
- Pregnant, as determined by a positive urine or serum beta human choriogonadotropin (beta-hCG) test (if female).
NOTE: Pregnancy is also a criterion for discontinuation of any further vaccine dosing
-
Menstruating females 11 years of age and younger. (In order to avoid cultural implications of further assessing pregnancy potential i.e. sexual activity in this age group.)
-
Behavioral, cognitive, or psychiatric disease that in the opinion of the investigator affects the ability of the subject to understand and comply with the study protocol at a level appropriate for the subject s age.
-
Hemoglobin, white blood cell (WBC), absolute neutrophil count, or platelet levels outside the local laboratory defined limits of normal. (Subjects may be included at the investigator s discretion for not clinically significant values outside of normal range and <= Grade 2.)
-
Alanine transaminase (ALT) or creatinine (Cr) level above the local laboratory defined upper limit of normal. (Subjects may be included at the investigator s discretion for not clinically significant values outside of normal range and <= Grade 2.)
-
Infected with HIV
-
Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, endocrine, rheumatologic, autoimmune, hematological, oncologic, or renal disease by history, physical examination, and/or laboratory studies including urinalysis.
-
Clinically significant prolonged QTc (>450 milliseconds) on screening EKG
-
History of receiving any investigational product within the past 30 days.
-
Current or planned participation in an investigational vaccine study until the last required protocol visit.
-
Medical, occupational, or family problems as a result of alcohol or illicit drug use during the past 12 months.
-
History of a severe allergic reaction or anaphylaxis.
-
Known:
-
Severe asthma, defined as asthma that is unstable or required emergent care, urgent care, hospitalization, or intubation during the past 2 years, or that has required the use of oral or parenteral corticosteroids at any time during the past 2 years.
-
Autoimmune or antibody-mediated disease including but not limited to: systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Sj(SqrRoot)(Delta)gren s syndrome, or autoimmune thrombocytopenia.
-
Immunodeficiency syndrome.
-
Seizure disorder (exception: history of simple febrile seizures)
-
Asplenia or functional asplenia.
-
Use of chronic (>=14 days) oral or intravenous (IV) corticosteroids (excluding topical or nasal) at immunosuppressive doses (i.e., prednisone >10 mg/day) or immunosuppressive drugs within 30 days of Study Day 0.
-
Allergy to latex or neomycin
-
Adverse reaction to hepatitis A and/or typhoid and/or meningococcal vaccine in the past
-
Adverse reaction to artemether/lumefantrine in the past
- Receipt of:
-Live vaccine within the past 4 weeks or a killed vaccine within the past 2 weeks to enrollment.
-
Immunoglobulins and/or blood products within the past 6 months.
-
Investigational malaria vaccine in the last 2 years.
- Any other condition that in the opinion of the investigator would jeopardize the safety or rights of a subject participating in the trial, interfere with the evaluation of the study objectives, or would render the subject unable to comply with the protocol.
Co-enrollment guidelines: Co-enrollment in other trials is restricted, other than enrollment on observational studies. Consideration for co-enrollment in trials evaluating the use of a licensed medication will require the approval of the PI. Study staff should be notified of co-enrollment on any other protocol as it may require the approval of the investigator.
Exclusion Criteria for Group 4:
An individual will be excluded from participating in this trial if any one of the following criteria is fulfilled:
-
Behavioral, cognitive, or psychiatric disease that in the opinion of the investigator affects the ability of the subject to understand and comply with the study protocol at a level appropriate for the subject s age.
-
Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, endocrine, rheumatologic, autoimmune, hematological, oncologic, or renal disease by history, physical examination, and/or laboratory studies including urinalysis.
-
Clinically significant prolonged QTc (by sex/age) on screening EKG
-
History of adverse reactions to artemether/lumefantrine in the past
-
History of receiving any investigational product within the past 30 days.
-
Current or planned participation in an investigational vaccine study until the last required protocol visit.
-
Receipt of:
-Investigational malaria vaccine in the last 2 years.
- Any other condition that in the opinion of the investigator would jeopardize the safety or rights of a subject participating in the trial, interfere with the evaluation of the study objectives, or would render the subject unable to comply with the protocol.
Exclusion Criteria for Groups 1, 2, 3 (Year 2):
An individual will be excluded from participating in this trial if any one of the following criteria is fulfilled:
- Pregnant, as determined by a positive urine or serum beta human choriogonadotropin (beta-hCG) test (if female).
NOTE: Pregnancy is also a criterion for discontinuation of any further vaccine dosing
-
Menstruating females 11 years of age and younger. (In order to avoid cultural implications of further assessing pregnancy potential i.e. sexual activity in this age group.)
-
Behavioral, cognitive, or psychiatric disease that in the opinion of the investigator affects the ability of the subject to understand and comply with the study protocol at a level appropriate for the subject s age.
-
Hemoglobin, white blood cell (WBC), absolute neutrophil count, or platelet levels outside the local laboratory defined limits of normal. (Subjects may be included at the investigator s discretion for not clinically significant values outside of normal range and less than or equal to Grade 2.)
-
Alanine transaminase (ALT) or creatinine (Cr) level above the local laboratory defined upper limit of normal. (Subjects may be included at the investigator s discretion for not clinically significant values outside of normal range and less than or equal to Grade 2.)
-
Infected with HIV
-
Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, endocrine, rheumatologic, autoimmune, hematological, oncologic, or renal disease by history, physical examination, and/or laboratory studies including urinalysis.
-
History of receiving any investigational product within the past 30 days.
-
Medical, occupational, or family problems as a result of alcohol or illicit drug use during the past 12 months.
-
History of a severe allergic reaction or anaphylaxis.
-
Known:
-Severe asthma, defined as asthma that is unstable or required emergent care, urgent care, hospitalization, or intubation during the past 2 years, or that has required the use of oral or parenteral corticosteroids at any time during the past 2 years.
-Autoimmune or antibody-mediated disease including but not limited to: systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Sjogren s syndrome, or autoimmune thrombocytopenia.
-
Immunodeficiency syndrome.
-
Seizure disorder (exception: history of simple febrile seizures)
-
Asplenia or functional asplenia.
-
Use of chronic (greater than or equal to 14 days) oral or intravenous (IV) corticosteroids (excluding topical or nasal) at immunosuppressive doses (i.e., prednisone >10 mg/day) or immunosuppressive drugs within 30 days of Study Day 0.
-
Allergy to latex or neomycin
-
Adverse reaction to hepatitis A and/or typhoid and/or meningococcal vaccine in the past
-
Adverse reaction to artemether/lumefantrine in the past
- Receipt of:
-
Live vaccine within the past 4 weeks or a killed vaccine within the past 2 weeks to enrollment.
-
Immunoglobulins and/or blood products within the past 6 months.
- Any other condition that in the opinion of the investigator would jeopardize the safety or rights of a subject participating in the trial, interfere with the evaluation of the study objectives, or would render the subject unable to comply with the protocol.
Exclusion Criteria for Group 4 (Year 2):
An individual will be excluded from participating in this trial if any one of the following criteria is fulfilled:
-
Behavioral, cognitive, or psychiatric disease that in the opinion of the investigator affects the ability of the subject to understand and comply with the study protocol at a level appropriate for the subject s age.
-
Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, endocrine, rheumatologic, autoimmune, hematological, oncologic, or renal disease by history, physical examination, and/or laboratory studies including urinalysis.
-
History of adverse reactions to artemether/lumefantrine in the past
-
History of receiving any investigational product within the past 30 days.
-
Current or planned participation in an investigational vaccine study until the last required protocol visit.
-
Receipt of:
- Investigational malaria vaccine in the last 2 years.
- Any other condition that in the opinion of the investigator would jeopardize the safety or rights of a subject participating in the trial, interfere with the evaluation of the study objectives, or would render the subject unable to comply with the protocol.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Mrtc/Usttb | Bamako | Mali |
Sponsors and Collaborators
- National Institute of Allergy and Infectious Diseases (NIAID)
Investigators
- Principal Investigator: Patrick E Duffy, M.D., National Institute of Allergy and Infectious Diseases (NIAID)
Study Documents (Full-Text)
More Information
Publications
- Farrance CE, Rhee A, Jones RM, Musiychuk K, Shamloul M, Sharma S, Mett V, Chichester JA, Streatfield SJ, Roeffen W, van de Vegte-Bolmer M, Sauerwein RW, Tsuboi T, Muratova OV, Wu Y, Yusibov V. A plant-produced Pfs230 vaccine candidate blocks transmission of Plasmodium falciparum. Clin Vaccine Immunol. 2011 Aug;18(8):1351-7. doi: 10.1128/CVI.05105-11. Epub 2011 Jun 29.
- MacDonald NJ, Nguyen V, Shimp R, Reiter K, Herrera R, Burkhardt M, Muratova O, Kumar K, Aebig J, Rausch K, Lambert L, Dawson N, Sattabongkot J, Ambroggio X, Duffy PE, Wu Y, Narum DL. Structural and Immunological Characterization of Recombinant 6-Cysteine Domains of the Plasmodium falciparum Sexual Stage Protein Pfs230. J Biol Chem. 2016 Sep 16;291(38):19913-22. doi: 10.1074/jbc.M116.732305. Epub 2016 Jul 18.
- Tachibana M, Wu Y, Iriko H, Muratova O, MacDonald NJ, Sattabongkot J, Takeo S, Otsuki H, Torii M, Tsuboi T. N-terminal prodomain of Pfs230 synthesized using a cell-free system is sufficient to induce complement-dependent malaria transmission-blocking activity. Clin Vaccine Immunol. 2011 Aug;18(8):1343-50. doi: 10.1128/CVI.05104-11. Epub 2011 Jun 29.
- 999919086
- 19-I-N086
Study Results
Participant Flow
| Recruitment Details | |
|---|---|
| Pre-assignment Detail |
| Arm/Group Title | Arm 1a | Arm 1b | Arm 2a | Arm 2b | Arm 3a | Arm 3b | Arm 3c | Arm 3d | Arm 3e | Arm 3f | Arm 4a | Arm 4b |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arm/Group Description | Pilot/safety: Dosing interval on days: 0, 28, 126, 448 Participants received 4 doses of 40 μg of Pfs230D1M-EPA/AS01 administered via intramuscular (IM) injection on days: 0, 28, 126, 448; receipt of artemether/lumefantrine (AL) on day -7 | Pilot/safety: Dosing interval on days: 0, 28, 126, 448 Participants received 4 doses administered via intramuscular (IM) injection on days 0, 448 to receive HAVRIX; day 28 to receove TYPHIM Vi; and day 126 to receive Menactra; receipt of AL on day -7 | Pilot/safety: Dosing interval on days: 0, 28, 126, 448 Participants received 4 doses administered via intramuscular (IM) injection on days 0, 28, 126, 448 to receive 40 μg of Pfs230D1M-EPA/AS01; receipt of AL on day -7,112, 441 | Pilot/safety: Dosing interval on days: 0, 28, 126, 448 Participants received 4 doses administered via intramuscular (IM) injection on days 0, 448 to receive HAVRIX; day 126 to receive Menactra; receipt of AL on day -7,112, 441 | Safety/efficacy: Dosing interval on days 0, 28, 56, 392 Participants received 4 doses administered via intramuscular (IM) injection on days 0, 28, 56, 392 to receive 40 μg of Pfs230D1M-EPA/AS01; receipt of AL on day -7, 42, 385 | Safety/efficacy: Dosing interval on days 0, 28, 56, 392 Participants received 4 doses administered via intramuscular (IM) injection on days 0, 392 to receive HAVRIX; day 28 TYPHIM Vi; day 56 to receive Menactra; receipt of AL on day -7, 42, 385 | Safety/efficacy: Dosing interval on days 0, 28, 56, 392 Participants received 4 doses administered via intramuscular (IM) injection on days 0, 28, 56, 392 to receive 40 μg of Pfs230D1M-EPA/AS01; receipt of AL on day -7 | Safety/efficacy: Dosing interval on days 0, 28, 56, 392 Participants received 4 doses administered via intramuscular (IM) injection on days 0, 392 to receive HAVRIX; day 28 TYPHIM Vi; day 56 to receive Menactra; receipt of AL on day -7 | Safety/efficacy: Dosing interval on days 0, 28, 56, 392 Participants received 4 doses administered via intramuscular (IM) injection on days 0, 28, 56, 392 to receive 40 μg of Pfs230D1M-EPA/AS01; receipt of AL on day -7 | Safety/efficacy: Dosing interval on days 0, 28, 56, 392 Participants received 4 doses administered via intramuscular (IM) injection on days 0, 392 to receive HAVRIX; day 28 TYPHIM Vi; day 56 to receive Menactra; receipt of AL on day -7 | AL treatment only; no vaccination Participants received AL on day -14, 385 | AL treatment only; no vaccination Participants received AL on day -14, 385 |
| Period Title: Year 1 | ||||||||||||
| STARTED | 15 | 15 | 15 | 15 | 99 | 87 | 192 | 177 | 227 | 267 | 97 | 95 |
| COMPLETED | 14 | 13 | 13 | 15 | 94 | 82 | 173 | 162 | 218 | 257 | 92 | 87 |
| NOT COMPLETED | 1 | 2 | 2 | 0 | 5 | 5 | 19 | 15 | 9 | 10 | 5 | 8 |
| Period Title: Year 1 | ||||||||||||
| STARTED | 13 | 10 | 13 | 14 | 86 | 77 | 152 | 147 | 199 | 238 | 90 | 87 |
| Did Not Rescreen | 1 | 3 | 0 | 1 | 8 | 5 | 21 | 15 | 19 | 19 | 2 | 0 |
| COMPLETED | 10 | 9 | 13 | 14 | 82 | 75 | 138 | 139 | 185 | 226 | 89 | 83 |
| NOT COMPLETED | 3 | 1 | 0 | 0 | 4 | 2 | 14 | 8 | 14 | 12 | 1 | 4 |
Baseline Characteristics
| Arm/Group Title | Arm 1a | Arm 1b | Arm 2a | Arm 2b | Arm 3a | Arm 3b | Arm 3c | Arm 3d | Arm 3e | Arm 3f | Arm 4a | Arm 4b | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arm/Group Description | Pilot/safety: Dosing interval on days: 0, 28, 126, 448 Participants received 4 doses of 40 μg of Pfs230D1M-EPA/AS01 administered via intramuscular (IM) injection on days: 0, 28, 126, 448; receipt of artemether/lumefantrine (AL) on day -7 | Pilot/safety: Dosing interval on days: 0, 28, 126, 448 Participants received 4 doses administered via intramuscular (IM) injection on days 0, 448 to receive HAVRIX; day 28 to receove TYPHIM Vi; and day 126 to receive Menactra; receipt of AL on day -7 | Pilot/safety: Dosing interval on days: 0, 28, 126, 448 Participants received 4 doses administered via intramuscular (IM) injection on days 0, 28, 126, 448 to receive 40 μg of Pfs230D1M-EPA/AS01; receipt of AL on day -7,112, 441 | Pilot/safety: Dosing interval on days: 0, 28, 126, 448 Participants received 4 doses administered via intramuscular (IM) injection on days 0, 448 to receive HAVRIX; day 126 to receive Menactra; receipt of AL on day -7,112, 441 | Safety/efficacy: Dosing interval on days 0, 28, 56, 392 Participants received 4 doses administered via intramuscular (IM) injection on days 0, 28, 56, 392 to receive 40 μg of Pfs230D1M-EPA/AS01; receipt of AL on day -7, 42, 385 | Safety/efficacy: Dosing interval on days 0, 28, 56, 392 Participants received 4 doses administered via intramuscular (IM) injection on days 0, 392 to receive HAVRIX; day 28 TYPHIM Vi; day 56 to receive Menactra; receipt of AL on day -7, 42, 385 | Safety/efficacy: Dosing interval on days 0, 28, 56, 392 Participants received 4 doses administered via intramuscular (IM) injection on days 0, 28, 56, 392 to receive 40 μg of Pfs230D1M-EPA/AS01; receipt of AL on day -7 | Safety/efficacy: Dosing interval on days 0, 28, 56, 392 Participants received 4 doses administered via intramuscular (IM) injection on days 0, 392 to receive HAVRIX; day 28 TYPHIM Vi; day 56 to receive Menactra; receipt of AL on day -7 | Safety/efficacy: Dosing interval on days 0, 28, 56, 392 Participants received 4 doses administered via intramuscular (IM) injection on days 0, 28, 56, 392 to receive 40 μg of Pfs230D1M-EPA/AS01; receipt of AL on day -7 | Safety/efficacy: Dosing interval on days 0, 28, 56, 392 Participants received 4 doses administered via intramuscular (IM) injection on days 0, 392 to receive HAVRIX; day 28 TYPHIM Vi; day 56 to receive Menactra; receipt of AL on day -7 | AL treatment only; no vaccination Participants received AL on day -14, 385 | AL treatment only; no vaccination Participants received AL on day -14, 385 | Total of all reporting groups |
| Overall Participants | 15 | 15 | 15 | 15 | 99 | 87 | 192 | 177 | 227 | 267 | 97 | 95 | 1301 |
| Age (Count of Participants) | |||||||||||||
| <=18 years |
15
100%
|
15
100%
|
15
100%
|
15
100%
|
99
100%
|
87
100%
|
178
92.7%
|
167
94.4%
|
0
0%
|
0
0%
|
97
100%
|
95
100%
|
783
60.2%
|
| Between 18 and 65 years |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
14
7.3%
|
10
5.6%
|
208
91.6%
|
249
93.3%
|
0
0%
|
0
0%
|
481
37%
|
| >=65 years |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
19
8.4%
|
18
6.7%
|
0
0%
|
0
0%
|
37
2.8%
|
| Sex: Female, Male (Count of Participants) | |||||||||||||
| Female |
6
40%
|
8
53.3%
|
5
33.3%
|
6
40%
|
50
50.5%
|
43
49.4%
|
84
43.8%
|
91
51.4%
|
126
55.5%
|
147
55.1%
|
44
45.4%
|
43
45.3%
|
653
50.2%
|
| Male |
9
60%
|
7
46.7%
|
10
66.7%
|
9
60%
|
49
49.5%
|
44
50.6%
|
108
56.3%
|
86
48.6%
|
101
44.5%
|
120
44.9%
|
53
54.6%
|
52
54.7%
|
648
49.8%
|
| Race/Ethnicity, Customized (Count of Participants) | |||||||||||||
| Bambara |
9
60%
|
11
73.3%
|
6
40%
|
2
13.3%
|
51
51.5%
|
34
39.1%
|
84
43.8%
|
51
28.8%
|
115
50.7%
|
139
52.1%
|
41
42.3%
|
32
33.7%
|
575
44.2%
|
| Sarakole |
6
40%
|
3
20%
|
8
53.3%
|
11
73.3%
|
45
45.5%
|
51
58.6%
|
93
48.4%
|
121
68.4%
|
98
43.2%
|
122
45.7%
|
45
46.4%
|
58
61.1%
|
661
50.8%
|
| Peulh |
0
0%
|
1
6.7%
|
1
6.7%
|
1
6.7%
|
2
2%
|
1
1.1%
|
12
6.3%
|
0
0%
|
8
3.5%
|
4
1.5%
|
5
5.2%
|
3
3.2%
|
38
2.9%
|
| Other |
0
0%
|
0
0%
|
0
0%
|
1
6.7%
|
0
0%
|
1
1.1%
|
0
0%
|
4
2.3%
|
0
0%
|
2
0.7%
|
0
0%
|
2
2.1%
|
10
0.8%
|
| Malinke |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
1
1%
|
0
0%
|
2
1%
|
1
0.6%
|
6
2.6%
|
0
0%
|
5
5.2%
|
0
0%
|
15
1.2%
|
| Bozo |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
1
0.5%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
1
0.1%
|
| Sonrhai |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
1
1%
|
0
0%
|
1
0.1%
|
| Region of Enrollment (participants) [Number] | |||||||||||||
| Mali |
15
100%
|
15
100%
|
15
100%
|
15
100%
|
99
100%
|
87
100%
|
192
100%
|
177
100%
|
227
100%
|
267
100%
|
97
100%
|
95
100%
|
1301
100%
|
Outcome Measures
| Title | Number of Participants With Local and Systemic Adverse Events in Years 1 and 2 |
|---|---|
| Description | Number of participants with local and systemic adverse events (AEs) graded by severity occurring within 7 days after each vaccine |
| Time Frame | Within 7 days after each vaccination |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Arm 1a | Arm 1b | Arm 2a | Arm 2b | Arm 3a | Arm 3b | Arm 3c | Arm 3d | Arm 3e | Arm 3f | Arm 4a | Arm 4b |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arm/Group Description | Pilot/safety: Dosing interval on days: 0, 28, 126, 448 Participants received 4 doses of 40 μg of Pfs230D1M-EPA/AS01 administered via intramuscular (IM) injection on days: 0, 28, 126, 448; receipt of artemether/lumefantrine (AL) on day -7 | Pilot/safety: Dosing interval on days: 0, 28, 126, 448 Participants received 4 doses administered via intramuscular (IM) injection on days 0, 448 to receive HAVRIX; day 28 to receove TYPHIM Vi; and day 126 to receive Menactra; receipt of AL on day -7 | Pilot/safety: Dosing interval on days: 0, 28, 126, 448 Participants received 4 doses administered via intramuscular (IM) injection on days 0, 28, 126, 448 to receive 40 μg of Pfs230D1M-EPA/AS01; receipt of AL on day -7,112, 441 | Pilot/safety: Dosing interval on days: 0, 28, 126, 448 Participants received 4 doses administered via intramuscular (IM) injection on days 0, 448 to receive HAVRIX; day 126 to receive Menactra; receipt of AL on day -7,112, 441 | Safety/efficacy: Dosing interval on days 0, 28, 56, 392 Participants received 4 doses administered via intramuscular (IM) injection on days 0, 28, 56, 392 to receive 40 μg of Pfs230D1M-EPA/AS01; receipt of AL on day -7, 42, 385 | Safety/efficacy: Dosing interval on days 0, 28, 56, 392 Participants received 4 doses administered via intramuscular (IM) injection on days 0, 392 to receive HAVRIX; day 28 TYPHIM Vi; day 56 to receive Menactra; receipt of AL on day -7, 42, 385 | Safety/efficacy: Dosing interval on days 0, 28, 56, 392 Participants received 4 doses administered via intramuscular (IM) injection on days 0, 28, 56, 392 to receive 40 μg of Pfs230D1M-EPA/AS01; receipt of AL on day -7 | Safety/efficacy: Dosing interval on days 0, 28, 56, 392 Participants received 4 doses administered via intramuscular (IM) injection on days 0, 392 to receive HAVRIX; day 28 TYPHIM Vi; day 56 to receive Menactra; receipt of AL on day -7 | Safety/efficacy: Dosing interval on days 0, 28, 56, 392 Participants received 4 doses administered via intramuscular (IM) injection on days 0, 28, 56, 392 to receive 40 μg of Pfs230D1M-EPA/AS01; receipt of AL on day -7 | Safety/efficacy: Dosing interval on days 0, 28, 56, 392 Participants received 4 doses administered via intramuscular (IM) injection on days 0, 392 to receive HAVRIX; day 28 TYPHIM Vi; day 56 to receive Menactra; receipt of AL on day -7 | AL treatment only; no vaccination Participants received AL on day -14, 385 | AL treatment only; no vaccination Participants received AL on day -14, 385 |
| Measure Participants | 15 | 15 | 15 | 15 | 99 | 87 | 192 | 177 | 227 | 267 | 97 | 95 |
| Count of Participants [Participants] |
15
100%
|
14
93.3%
|
15
100%
|
15
100%
|
96
97%
|
85
97.7%
|
187
97.4%
|
172
97.2%
|
224
98.7%
|
260
97.4%
|
89
91.8%
|
85
89.5%
|
Adverse Events
| Time Frame | 2 years | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adverse Event Reporting Description | ||||||||||||||||||||||||
| Arm/Group Title | Arm 1a | Arm 1b | Arm 2a | Arm 2b | Arm 3a | Arm 3b | Arm 3c | Arm 3d | Arm 3e | Arm 3f | Arm 4a | Arm 4b | ||||||||||||
| Arm/Group Description | Pilot/safety: Dosing interval on days: 0, 28, 126, 448 Participants received 4 doses of 40 μg of Pfs230D1M-EPA/AS01 administered via intramuscular (IM) injection on days: 0, 28, 126, 448; receipt of artemether/lumefantrine (AL) on day -7 | Pilot/safety: Dosing interval on days: 0, 28, 126, 448 Participants received 4 doses administered via intramuscular (IM) injection on days 0, 448 to receive HAVRIX; day 28 to receove TYPHIM Vi; and day 126 to receive Menactra; receipt of AL on day -7 | Pilot/safety: Dosing interval on days: 0, 28, 126, 448 Participants received 4 doses administered via intramuscular (IM) injection on days 0, 28, 126, 448 to receive 40 μg of Pfs230D1M-EPA/AS01; receipt of AL on day -7,112, 441 | Pilot/safety: Dosing interval on days: 0, 28, 126, 448 Participants received 4 doses administered via intramuscular (IM) injection on days 0, 448 to receive HAVRIX; day 126 to receive Menactra; receipt of AL on day -7,112, 441 | Safety/efficacy: Dosing interval on days 0, 28, 56, 392 Participants received 4 doses administered via intramuscular (IM) injection on days 0, 28, 56, 392 to receive 40 μg of Pfs230D1M-EPA/AS01; receipt of AL on day -7, 42, 385 | Safety/efficacy: Dosing interval on days 0, 28, 56, 392 Participants received 4 doses administered via intramuscular (IM) injection on days 0, 392 to receive HAVRIX; day 28 TYPHIM Vi; day 56 to receive Menactra; receipt of AL on day -7, 42, 385 | Safety/efficacy: Dosing interval on days 0, 28, 56, 392 Participants received 4 doses administered via intramuscular (IM) injection on days 0, 28, 56, 392 to receive 40 μg of Pfs230D1M-EPA/AS01; receipt of AL on day -7 | Safety/efficacy: Dosing interval on days 0, 28, 56, 392 Participants received 4 doses administered via intramuscular (IM) injection on days 0, 392 to receive HAVRIX; day 28 TYPHIM Vi; day 56 to receive Menactra; receipt of AL on day -7 | Safety/efficacy: Dosing interval on days 0, 28, 56, 392 Participants received 4 doses administered via intramuscular (IM) injection on days 0, 28, 56, 392 to receive 40 μg of Pfs230D1M-EPA/AS01; receipt of AL on day -7 | Safety/efficacy: Dosing interval on days 0, 28, 56, 392 Participants received 4 doses administered via intramuscular (IM) injection on days 0, 392 to receive HAVRIX; day 28 TYPHIM Vi; day 56 to receive Menactra; receipt of AL on day -7 | AL treatment only; no vaccination Participants received AL on day -14, 385 | AL treatment only; no vaccination Participants received AL on day -14, 385 | ||||||||||||
All Cause Mortality |
||||||||||||||||||||||||
| Arm 1a | Arm 1b | Arm 2a | Arm 2b | Arm 3a | Arm 3b | Arm 3c | Arm 3d | Arm 3e | Arm 3f | Arm 4a | Arm 4b | |||||||||||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 1/87 (1.1%) | 0/192 (0%) | 0/177 (0%) | 2/227 (0.9%) | 5/267 (1.9%) | 0/97 (0%) | 0/95 (0%) | ||||||||||||
Serious Adverse Events |
||||||||||||||||||||||||
| Arm 1a | Arm 1b | Arm 2a | Arm 2b | Arm 3a | Arm 3b | Arm 3c | Arm 3d | Arm 3e | Arm 3f | Arm 4a | Arm 4b | |||||||||||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 1/99 (1%) | 1/87 (1.1%) | 0/192 (0%) | 2/177 (1.1%) | 2/227 (0.9%) | 7/267 (2.6%) | 0/97 (0%) | 1/95 (1.1%) | ||||||||||||
| Blood and lymphatic system disorders | ||||||||||||||||||||||||
| Blood Creatinine Increased | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 0/87 (0%) | 0/192 (0%) | 0/177 (0%) | 0/227 (0%) | 1/267 (0.4%) | 1 | 0/97 (0%) | 1 | 0/95 (0%) | 1 | |||||||||
| Gastrointestinal disorders | ||||||||||||||||||||||||
| ESOPHAGEAL STENOSIS | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 0/87 (0%) | 0/192 (0%) | 0/177 (0%) | 0/227 (0%) | 1/267 (0.4%) | 1 | 0/97 (0%) | 1 | 0/95 (0%) | 1 | |||||||||
| Pancreatic carcinoma | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 0/87 (0%) | 0/192 (0%) | 0/177 (0%) | 0/227 (0%) | 1/267 (0.4%) | 1 | 0/97 (0%) | 1 | 0/95 (0%) | 1 | |||||||||
| Infections and infestations | ||||||||||||||||||||||||
| Bacterial Infection | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 0/87 (0%) | 0/192 (0%) | 0/177 (0%) | 1/227 (0.4%) | 1 | 0/267 (0%) | 1 | 0/97 (0%) | 1 | 0/95 (0%) | 1 | ||||||||
| Malaria | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 0/87 (0%) | 0/192 (0%) | 0/177 (0%) | 0/227 (0%) | 0/267 (0%) | 0/97 (0%) | 1/95 (1.1%) | 1 | |||||||||||
| Injury, poisoning and procedural complications | ||||||||||||||||||||||||
| Gun shot wound | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 0/87 (0%) | 0/192 (0%) | 0/177 (0%) | 0/227 (0%) | 1/267 (0.4%) | 1 | 0/97 (0%) | 1 | 0/95 (0%) | 1 | |||||||||
| Pelvic fracture | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 0/87 (0%) | 0/192 (0%) | 1/177 (0.6%) | 1 | 0/227 (0%) | 1 | 0/267 (0%) | 1 | 0/97 (0%) | 1 | 0/95 (0%) | 1 | |||||||
| Wrist fracture | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 1/99 (1%) | 1 | 0/87 (0%) | 1 | 0/192 (0%) | 1 | 0/177 (0%) | 1 | 0/227 (0%) | 1 | 0/267 (0%) | 1 | 0/97 (0%) | 1 | 0/95 (0%) | 1 | ||||
| Nervous system disorders | ||||||||||||||||||||||||
| Cerebrovascular accident | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 0/87 (0%) | 0/192 (0%) | 0/177 (0%) | 0/227 (0%) | 1/267 (0.4%) | 1 | 0/97 (0%) | 1 | 0/95 (0%) | 1 | |||||||||
| Struck by lightning | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 0/87 (0%) | 0/192 (0%) | 0/177 (0%) | 0/227 (0%) | 1/267 (0.4%) | 1 | 0/97 (0%) | 1 | 0/95 (0%) | 1 | |||||||||
| Pregnancy, puerperium and perinatal conditions | ||||||||||||||||||||||||
| Retained placenta or membranes | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 0/87 (0%) | 0/192 (0%) | 1/177 (0.6%) | 1 | 0/227 (0%) | 1 | 0/267 (0%) | 1 | 0/97 (0%) | 1 | 0/95 (0%) | 1 | |||||||
| Reproductive system and breast disorders | ||||||||||||||||||||||||
| Prostate adenoma | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 0/87 (0%) | 0/192 (0%) | 0/177 (0%) | 0/227 (0%) | 1/267 (0.4%) | 1 | 0/97 (0%) | 1 | 0/95 (0%) | 1 | |||||||||
| Respiratory, thoracic and mediastinal disorders | ||||||||||||||||||||||||
| Drowning | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 1/87 (1.1%) | 1 | 0/192 (0%) | 1 | 0/177 (0%) | 1 | 0/227 (0%) | 1 | 0/267 (0%) | 1 | 0/97 (0%) | 1 | 0/95 (0%) | 1 | |||||
| Dyspnea | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 0/87 (0%) | 0/192 (0%) | 0/177 (0%) | 1/227 (0.4%) | 1 | 0/267 (0%) | 1 | 0/97 (0%) | 1 | 0/95 (0%) | 1 | ||||||||
Other (Not Including Serious) Adverse Events |
||||||||||||||||||||||||
| Arm 1a | Arm 1b | Arm 2a | Arm 2b | Arm 3a | Arm 3b | Arm 3c | Arm 3d | Arm 3e | Arm 3f | Arm 4a | Arm 4b | |||||||||||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 15/15 (100%) | 14/15 (93.3%) | 15/15 (100%) | 15/15 (100%) | 95/99 (96%) | 84/87 (96.6%) | 187/192 (97.4%) | 170/177 (96%) | 222/227 (97.8%) | 253/267 (94.8%) | 89/97 (91.8%) | 84/95 (88.4%) | ||||||||||||
| Blood and lymphatic system disorders | ||||||||||||||||||||||||
| Alanine aminotransferase increased | 1/15 (6.7%) | 2 | 0/15 (0%) | 2 | 0/15 (0%) | 2 | 0/15 (0%) | 2 | 5/99 (5.1%) | 5 | 5/87 (5.7%) | 5 | 6/192 (3.1%) | 7 | 3/177 (1.7%) | 3 | 8/227 (3.5%) | 12 | 9/267 (3.4%) | 9 | 0/97 (0%) | 9 | 0/95 (0%) | 9 |
| Blood creatinine inreased | 0/15 (0%) | 0 | 1/15 (6.7%) | 1 | 0/15 (0%) | 1 | 0/15 (0%) | 1 | 0/99 (0%) | 1 | 0/87 (0%) | 1 | 2/192 (1%) | 2 | 0/177 (0%) | 2 | 12/227 (5.3%) | 15 | 22/267 (8.2%) | 28 | 0/97 (0%) | 28 | 0/95 (0%) | 28 |
| Hemoglobin decreased | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 3/99 (3%) | 3 | 3/87 (3.4%) | 5 | 5/192 (2.6%) | 7 | 3/177 (1.7%) | 3 | 6/227 (2.6%) | 9 | 3/267 (1.1%) | 3 | 0/97 (0%) | 3 | 0/95 (0%) | 3 | ||||
| Leukocytosis | 2/15 (13.3%) | 2 | 0/15 (0%) | 2 | 0/15 (0%) | 2 | 0/15 (0%) | 2 | 0/99 (0%) | 2 | 3/87 (3.4%) | 3 | 5/192 (2.6%) | 6 | 3/177 (1.7%) | 5 | 6/227 (2.6%) | 7 | 3/267 (1.1%) | 3 | 0/97 (0%) | 3 | 0/95 (0%) | 3 |
| Leukopenia | 2/15 (13.3%) | 3 | 1/15 (6.7%) | 1 | 0/15 (0%) | 1 | 1/15 (6.7%) | 1 | 1/99 (1%) | 1 | 6/87 (6.9%) | 6 | 15/192 (7.8%) | 22 | 20/177 (11.3%) | 25 | 28/227 (12.3%) | 50 | 40/267 (15%) | 61 | 0/97 (0%) | 61 | 0/95 (0%) | 61 |
| Neutropenia | 3/15 (20%) | 7 | 2/15 (13.3%) | 2 | 2/15 (13.3%) | 2 | 3/15 (20%) | 5 | 4/99 (4%) | 5 | 11/87 (12.6%) | 12 | 20/192 (10.4%) | 33 | 33/177 (18.6%) | 41 | 38/227 (16.7%) | 59 | 53/267 (19.9%) | 84 | 0/97 (0%) | 84 | 0/95 (0%) | 84 |
| Thrombocytopenia | 1/15 (6.7%) | 2 | 0/15 (0%) | 2 | 0/15 (0%) | 2 | 0/15 (0%) | 2 | 6/99 (6.1%) | 7 | 4/87 (4.6%) | 4 | 8/192 (4.2%) | 8 | 5/177 (2.8%) | 6 | 6/227 (2.6%) | 8 | 9/267 (3.4%) | 16 | 0/97 (0%) | 16 | 0/95 (0%) | 16 |
| Cardiac disorders | ||||||||||||||||||||||||
| Tachycardia | 3/15 (20%) | 3 | 0/15 (0%) | 3 | 0/15 (0%) | 3 | 0/15 (0%) | 3 | 1/99 (1%) | 2 | 3/87 (3.4%) | 4 | 0/192 (0%) | 4 | 0/177 (0%) | 4 | 0/227 (0%) | 4 | 0/267 (0%) | 4 | 4/97 (4.1%) | 5 | 2/95 (2.1%) | 3 |
| Ear and labyrinth disorders | ||||||||||||||||||||||||
| Foreign body in ear | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 0/87 (0%) | 0/192 (0%) | 0/177 (0%) | 0/227 (0%) | 0/267 (0%) | 1/97 (1%) | 1 | 0/95 (0%) | 1 | ||||||||||
| Otitis externa | 0/15 (0%) | 0 | 1/15 (6.7%) | 1 | 0/15 (0%) | 1 | 1/15 (6.7%) | 1 | 0/99 (0%) | 1 | 1/87 (1.1%) | 1 | 1/192 (0.5%) | 1 | 1/177 (0.6%) | 1 | 3/227 (1.3%) | 4 | 2/267 (0.7%) | 2 | 0/97 (0%) | 2 | 0/95 (0%) | 2 |
| Otitis media | 0/15 (0%) | 0 | 0/15 (0%) | 0 | 1/15 (6.7%) | 1 | 1/15 (6.7%) | 1 | 2/99 (2%) | 2 | 1/87 (1.1%) | 1 | 2/192 (1%) | 2 | 2/177 (1.1%) | 2 | 1/227 (0.4%) | 1 | 3/267 (1.1%) | 3 | 0/97 (0%) | 3 | 3/95 (3.2%) | 3 |
| Parotitis | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 0/87 (0%) | 0/192 (0%) | 0/177 (0%) | 0/227 (0%) | 0/267 (0%) | 1/97 (1%) | 1 | 0/95 (0%) | 1 | ||||||||||
| Eye disorders | ||||||||||||||||||||||||
| Conjunctivitis | 0/15 (0%) | 0 | 0/15 (0%) | 0 | 0/15 (0%) | 0 | 0/15 (0%) | 0 | 4/99 (4%) | 4 | 1/87 (1.1%) | 1 | 2/192 (1%) | 2 | 0/177 (0%) | 2 | 1/227 (0.4%) | 1 | 2/267 (0.7%) | 2 | 1/97 (1%) | 1 | 2/95 (2.1%) | 2 |
| Hordeolum | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 0/87 (0%) | 1/192 (0.5%) | 1 | 1/177 (0.6%) | 1 | 1/227 (0.4%) | 1 | 0/267 (0%) | 1 | 0/97 (0%) | 1 | 0/95 (0%) | 1 | ||||||
| Gastrointestinal disorders | ||||||||||||||||||||||||
| Decreased appetite | 0/15 (0%) | 0 | 1/15 (6.7%) | 1 | 0/15 (0%) | 1 | 0/15 (0%) | 1 | 0/99 (0%) | 1 | 0/87 (0%) | 1 | 3/192 (1.6%) | 3 | 4/177 (2.3%) | 4 | 18/227 (7.9%) | 20 | 20/267 (7.5%) | 22 | 1/97 (1%) | 1 | 1/95 (1.1%) | 1 |
| Dental caries | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 1/15 (6.7%) | 1 | 0/99 (0%) | 1 | 0/87 (0%) | 1 | 5/192 (2.6%) | 7 | 7/177 (4%) | 8 | 12/227 (5.3%) | 14 | 14/267 (5.2%) | 14 | 0/97 (0%) | 14 | 0/95 (0%) | 14 | |||
| Diarrhea | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 0/87 (0%) | 0/192 (0%) | 0/177 (0%) | 3/227 (1.3%) | 3 | 1/267 (0.4%) | 1 | 2/97 (2.1%) | 2 | 1/95 (1.1%) | 1 | ||||||||
| Dysentery | 0/15 (0%) | 1/15 (6.7%) | 1 | 0/15 (0%) | 1 | 0/15 (0%) | 1 | 1/99 (1%) | 1 | 1/87 (1.1%) | 1 | 0/192 (0%) | 1 | 2/177 (1.1%) | 2 | 9/227 (4%) | 9 | 14/267 (5.2%) | 14 | 2/97 (2.1%) | 2 | 0/95 (0%) | 2 | |
| Gastric ulcer | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 0/87 (0%) | 0/192 (0%) | 0/177 (0%) | 1/227 (0.4%) | 1 | 1/267 (0.4%) | 1 | 0/97 (0%) | 1 | 0/95 (0%) | 1 | ||||||||
| Gastritis | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 0/87 (0%) | 0/192 (0%) | 0/177 (0%) | 1/227 (0.4%) | 2 | 3/267 (1.1%) | 3 | 0/97 (0%) | 3 | 0/95 (0%) | 3 | ||||||||
| Gastroenteritis | 0/15 (0%) | 0/15 (0%) | 3/15 (20%) | 3 | 0/15 (0%) | 3 | 8/99 (8.1%) | 8 | 9/87 (10.3%) | 11 | 10/192 (5.2%) | 10 | 13/177 (7.3%) | 14 | 18/227 (7.9%) | 20 | 22/267 (8.2%) | 25 | 12/97 (12.4%) | 13 | 10/95 (10.5%) | 11 | ||
| Gingivitis | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 0/87 (0%) | 0/192 (0%) | 1/177 (0.6%) | 1 | 0/227 (0%) | 1 | 0/267 (0%) | 1 | 0/97 (0%) | 1 | 0/95 (0%) | 1 | |||||||
| Malnutrition | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 0/87 (0%) | 0/192 (0%) | 0/177 (0%) | 0/227 (0%) | 1/267 (0.4%) | 1 | 0/97 (0%) | 1 | 0/95 (0%) | 1 | |||||||||
| Nausea | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 0/87 (0%) | 2/192 (1%) | 2 | 0/177 (0%) | 2 | 5/227 (2.2%) | 5 | 6/267 (2.2%) | 7 | 0/97 (0%) | 7 | 0/95 (0%) | 7 | ||||||
| Oropharyngeal pain | 0/15 (0%) | 0 | 0/15 (0%) | 0 | 0/15 (0%) | 0 | 0/15 (0%) | 0 | 2/99 (2%) | 2 | 1/87 (1.1%) | 1 | 3/192 (1.6%) | 3 | 1/177 (0.6%) | 1 | 1/227 (0.4%) | 1 | 1/267 (0.4%) | 1 | 1/97 (1%) | 1 | 0/95 (0%) | 1 |
| Pharyngitis | 4/15 (26.7%) | 5 | 1/15 (6.7%) | 1 | 7/15 (46.7%) | 9 | 7/15 (46.7%) | 14 | 30/99 (30.3%) | 43 | 29/87 (33.3%) | 38 | 29/192 (15.1%) | 35 | 36/177 (20.3%) | 50 | 24/227 (10.6%) | 26 | 20/267 (7.5%) | 23 | 23/97 (23.7%) | 29 | 25/95 (26.3%) | 29 |
| Tonsilitis | 0/15 (0%) | 0/15 (0%) | 1/15 (6.7%) | 1 | 0/15 (0%) | 1 | 2/99 (2%) | 2 | 1/87 (1.1%) | 1 | 1/192 (0.5%) | 1 | 3/177 (1.7%) | 3 | 0/227 (0%) | 3 | 3/267 (1.1%) | 3 | 1/97 (1%) | 1 | 1/95 (1.1%) | 1 | ||
| Toothache | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 1/99 (1%) | 1 | 0/87 (0%) | 1 | 0/192 (0%) | 1 | 0/177 (0%) | 1 | 0/227 (0%) | 1 | 1/267 (0.4%) | 1 | 0/97 (0%) | 1 | 0/95 (0%) | 1 | ||||
| Vomiting | 0/15 (0%) | 0/15 (0%) | 3/15 (20%) | 3 | 0/15 (0%) | 3 | 4/99 (4%) | 4 | 3/87 (3.4%) | 3 | 6/192 (3.1%) | 6 | 2/177 (1.1%) | 2 | 7/227 (3.1%) | 7 | 6/267 (2.2%) | 6 | 3/97 (3.1%) | 3 | 5/95 (5.3%) | 5 | ||
| General disorders | ||||||||||||||||||||||||
| Chest pain | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 0/87 (0%) | 0/192 (0%) | 1/177 (0.6%) | 1 | 0/227 (0%) | 1 | 0/267 (0%) | 1 | 0/97 (0%) | 1 | 0/95 (0%) | 1 | |||||||
| Fatigue | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 0/87 (0%) | 1/192 (0.5%) | 1 | 0/177 (0%) | 1 | 13/227 (5.7%) | 13 | 4/267 (1.5%) | 4 | 0/97 (0%) | 4 | 0/95 (0%) | 4 | ||||||
| Pyrexia | 2/15 (13.3%) | 2 | 1/15 (6.7%) | 1 | 7/15 (46.7%) | 9 | 2/15 (13.3%) | 2 | 29/99 (29.3%) | 34 | 11/87 (12.6%) | 13 | 36/192 (18.8%) | 44 | 8/177 (4.5%) | 10 | 34/227 (15%) | 37 | 19/267 (7.1%) | 19 | 16/97 (16.5%) | 17 | 5/95 (5.3%) | 5 |
| Immune system disorders | ||||||||||||||||||||||||
| Inflammation | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 0/87 (0%) | 0/192 (0%) | 0/177 (0%) | 0/227 (0%) | 1/267 (0.4%) | 1 | 0/97 (0%) | 1 | 0/95 (0%) | 1 | |||||||||
| Infections and infestations | ||||||||||||||||||||||||
| Abscess | 0/15 (0%) | 0 | 0/15 (0%) | 0 | 0/15 (0%) | 0 | 0/15 (0%) | 0 | 0/99 (0%) | 0 | 0/87 (0%) | 0 | 2/192 (1%) | 2 | 0/177 (0%) | 2 | 0/227 (0%) | 2 | 1/267 (0.4%) | 1 | 1/97 (1%) | 1 | 0/95 (0%) | 1 |
| Abscess limb | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 0/87 (0%) | 0/192 (0%) | 3/177 (1.7%) | 3 | 0/227 (0%) | 3 | 0/267 (0%) | 3 | 0/97 (0%) | 3 | 0/95 (0%) | 3 | |||||||
| Ear infection | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 2/99 (2%) | 3 | 0/87 (0%) | 3 | 1/192 (0.5%) | 1 | 1/177 (0.6%) | 1 | 0/227 (0%) | 1 | 0/267 (0%) | 1 | 1/97 (1%) | 1 | 0/95 (0%) | 1 | ||||
| Fungal infection | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 0/87 (0%) | 0/192 (0%) | 0/177 (0%) | 0/227 (0%) | 1/267 (0.4%) | 1 | 0/97 (0%) | 1 | 0/95 (0%) | 1 | |||||||||
| Genital infection | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 0/87 (0%) | 1/192 (0.5%) | 1 | 0/177 (0%) | 1 | 1/227 (0.4%) | 1 | 5/267 (1.9%) | 5 | 0/97 (0%) | 5 | 0/95 (0%) | 5 | ||||||
| Infection parasitic | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 0/87 (0%) | 0/192 (0%) | 0/177 (0%) | 0/227 (0%) | 1/267 (0.4%) | 1 | 0/97 (0%) | 1 | 0/95 (0%) | 1 | |||||||||
| Malaria | 13/15 (86.7%) | 31 | 11/15 (73.3%) | 21 | 10/15 (66.7%) | 26 | 10/15 (66.7%) | 16 | 70/99 (70.7%) | 155 | 61/87 (70.1%) | 128 | 148/192 (77.1%) | 316 | 120/177 (67.8%) | 241 | 104/227 (45.8%) | 149 | 137/267 (51.3%) | 184 | 48/97 (49.5%) | 81 | 46/95 (48.4%) | 69 |
| Paronychia | 0/15 (0%) | 0 | 0/15 (0%) | 0 | 0/15 (0%) | 0 | 0/15 (0%) | 0 | 0/99 (0%) | 0 | 0/87 (0%) | 0 | 0/192 (0%) | 0 | 0/177 (0%) | 0 | 0/227 (0%) | 0 | 2/267 (0.7%) | 2 | 1/97 (1%) | 1 | 0/95 (0%) | 1 |
| Typhoid fever | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 3/99 (3%) | 3 | 0/87 (0%) | 3 | 1/192 (0.5%) | 1 | 1/177 (0.6%) | 1 | 0/227 (0%) | 1 | 1/267 (0.4%) | 1 | 0/97 (0%) | 1 | 0/95 (0%) | 1 | ||||
| Varicella | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 2/87 (2.3%) | 2 | 0/192 (0%) | 2 | 0/177 (0%) | 2 | 0/227 (0%) | 2 | 0/267 (0%) | 2 | 0/97 (0%) | 2 | 0/95 (0%) | 2 | |||||
| Wound infection | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 1/15 (6.7%) | 1 | 3/99 (3%) | 3 | 1/87 (1.1%) | 1 | 5/192 (2.6%) | 5 | 3/177 (1.7%) | 3 | 3/227 (1.3%) | 3 | 3/267 (1.1%) | 3 | 1/97 (1%) | 1 | 1/95 (1.1%) | 1 | |||
| Injury, poisoning and procedural complications | ||||||||||||||||||||||||
| Eye injury | 0/15 (0%) | 0/15 (0%) | 1/15 (6.7%) | 1 | 0/15 (0%) | 1 | 0/99 (0%) | 1 | 0/87 (0%) | 1 | 0/192 (0%) | 1 | 0/177 (0%) | 1 | 0/227 (0%) | 1 | 0/267 (0%) | 1 | 0/97 (0%) | 1 | 0/95 (0%) | 1 | ||
| Food poisoning | 1/15 (6.7%) | 1 | 0/15 (0%) | 1 | 0/15 (0%) | 1 | 0/15 (0%) | 1 | 1/99 (1%) | 1 | 0/87 (0%) | 1 | 0/192 (0%) | 1 | 2/177 (1.1%) | 2 | 0/227 (0%) | 2 | 2/267 (0.7%) | 2 | 0/97 (0%) | 2 | 1/95 (1.1%) | 1 |
| Limb injury | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 0/87 (0%) | 1/192 (0.5%) | 1 | 1/177 (0.6%) | 1 | 1/227 (0.4%) | 1 | 2/267 (0.7%) | 2 | 0/97 (0%) | 2 | 0/95 (0%) | 2 | ||||||
| Poisoning | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 1/87 (1.1%) | 1 | 0/192 (0%) | 1 | 0/177 (0%) | 1 | 0/227 (0%) | 1 | 0/267 (0%) | 1 | 0/97 (0%) | 1 | 0/95 (0%) | 1 | |||||
| Snake bite | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 0/87 (0%) | 0/192 (0%) | 0/177 (0%) | 2/227 (0.9%) | 2 | 1/267 (0.4%) | 1 | 0/97 (0%) | 1 | 0/95 (0%) | 1 | ||||||||
| Thermal burn | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 1/87 (1.1%) | 1 | 0/192 (0%) | 1 | 0/177 (0%) | 1 | 1/227 (0.4%) | 1 | 1/267 (0.4%) | 1 | 0/97 (0%) | 1 | 0/95 (0%) | 1 | |||||
| Musculoskeletal and connective tissue disorders | ||||||||||||||||||||||||
| Abdominal Pain | 1/15 (6.7%) | 1 | 2/15 (13.3%) | 2 | 2/15 (13.3%) | 3 | 2/15 (13.3%) | 4 | 15/99 (15.2%) | 18 | 19/87 (21.8%) | 25 | 24/192 (12.5%) | 26 | 24/177 (13.6%) | 30 | 8/227 (3.5%) | 8 | 16/267 (6%) | 17 | 8/97 (8.2%) | 9 | 6/95 (6.3%) | 6 |
| Abdominal Pain Upper | 0/15 (0%) | 0 | 0/15 (0%) | 0 | 0/15 (0%) | 0 | 0/15 (0%) | 0 | 0/99 (0%) | 0 | 0/87 (0%) | 0 | 0/192 (0%) | 0 | 1/177 (0.6%) | 1 | 2/227 (0.9%) | 2 | 3/267 (1.1%) | 3 | 0/97 (0%) | 3 | 0/95 (0%) | 3 |
| Arthralgia | 1/15 (6.7%) | 1 | 0/15 (0%) | 1 | 0/15 (0%) | 1 | 0/15 (0%) | 1 | 0/99 (0%) | 1 | 0/87 (0%) | 1 | 0/192 (0%) | 1 | 0/177 (0%) | 1 | 7/227 (3.1%) | 8 | 9/267 (3.4%) | 9 | 0/97 (0%) | 9 | 0/95 (0%) | 9 |
| Asthenia | 0/15 (0%) | 0 | 0/15 (0%) | 0 | 0/15 (0%) | 0 | 0/15 (0%) | 0 | 0/99 (0%) | 0 | 0/87 (0%) | 0 | 0/192 (0%) | 0 | 1/177 (0.6%) | 3 | 7/227 (3.1%) | 7 | 8/267 (3%) | 8 | 0/97 (0%) | 8 | 0/95 (0%) | 8 |
| Back pain | 0/15 (0%) | 0 | 0/15 (0%) | 0 | 0/15 (0%) | 0 | 0/15 (0%) | 0 | 0/99 (0%) | 0 | 0/87 (0%) | 0 | 0/192 (0%) | 0 | 1/177 (0.6%) | 1 | 4/227 (1.8%) | 5 | 6/267 (2.2%) | 6 | 0/97 (0%) | 6 | 0/95 (0%) | 6 |
| Forearm fracture | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 1/87 (1.1%) | 1 | 0/192 (0%) | 1 | 0/177 (0%) | 1 | 0/227 (0%) | 1 | 0/267 (0%) | 1 | 0/97 (0%) | 1 | 0/95 (0%) | 1 | |||||
| Fracture | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 1/15 (6.7%) | 1 | 0/99 (0%) | 1 | 0/87 (0%) | 1 | 0/192 (0%) | 1 | 0/177 (0%) | 1 | 0/227 (0%) | 1 | 0/267 (0%) | 1 | 0/97 (0%) | 1 | 0/95 (0%) | 1 | |||
| Injection site edema | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 0/87 (0%) | 0/192 (0%) | 0/177 (0%) | 0/227 (0%) | 1/267 (0.4%) | 1 | 0/97 (0%) | 1 | 0/95 (0%) | 1 | |||||||||
| Injection site movement impairment | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 0/87 (0%) | 0/192 (0%) | 0/177 (0%) | 1/227 (0.4%) | 1 | 0/267 (0%) | 1 | 0/97 (0%) | 1 | 0/95 (0%) | 1 | ||||||||
| Injection site pain | 15/15 (100%) | 37 | 11/15 (73.3%) | 21 | 15/15 (100%) | 31 | 12/15 (80%) | 19 | 80/99 (80.8%) | 148 | 46/87 (52.9%) | 74 | 148/192 (77.1%) | 247 | 78/177 (44.1%) | 105 | 152/227 (67%) | 245 | 85/267 (31.8%) | 106 | 0/97 (0%) | 106 | 0/95 (0%) | 106 |
| Injection site pruritis | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 0/87 (0%) | 0/192 (0%) | 0/177 (0%) | 1/227 (0.4%) | 1 | 3/267 (1.1%) | 3 | 0/97 (0%) | 3 | 0/95 (0%) | 3 | ||||||||
| Injection site swelling | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 0/87 (0%) | 0/192 (0%) | 0/177 (0%) | 0/227 (0%) | 1/267 (0.4%) | 1 | 0/97 (0%) | 1 | 0/95 (0%) | 1 | |||||||||
| Joint dislocation | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 1/99 (1%) | 1 | 0/87 (0%) | 1 | 0/192 (0%) | 1 | 0/177 (0%) | 1 | 0/227 (0%) | 1 | 0/267 (0%) | 1 | 0/97 (0%) | 1 | 0/95 (0%) | 1 | ||||
| Ligament sprain | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 1/99 (1%) | 1 | 0/87 (0%) | 1 | 0/192 (0%) | 1 | 0/177 (0%) | 1 | 2/227 (0.9%) | 2 | 0/267 (0%) | 2 | 0/97 (0%) | 2 | 0/95 (0%) | 2 | ||||
| Myalgia | 1/15 (6.7%) | 2 | 0/15 (0%) | 2 | 0/15 (0%) | 2 | 0/15 (0%) | 2 | 0/99 (0%) | 2 | 0/87 (0%) | 2 | 1/192 (0.5%) | 1 | 1/177 (0.6%) | 1 | 17/227 (7.5%) | 18 | 16/267 (6%) | 22 | 0/97 (0%) | 22 | 0/95 (0%) | 22 |
| Sciatica | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 0/87 (0%) | 0/192 (0%) | 1/177 (0.6%) | 1 | 4/227 (1.8%) | 4 | 0/267 (0%) | 0 | 0/97 (0%) | 0 | 0/95 (0%) | 0 | |||||||
| Nervous system disorders | ||||||||||||||||||||||||
| Chills | 1/15 (6.7%) | 1 | 0/15 (0%) | 0 | 0/15 (0%) | 0 | 0/15 (0%) | 0 | 0/99 (0%) | 0 | 0/87 (0%) | 0 | 4/192 (2.1%) | 6 | 5/177 (2.8%) | 5 | 9/227 (4%) | 9 | 13/267 (4.9%) | 13 | 0/97 (0%) | 13 | 0/95 (0%) | 13 |
| Dizziness | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 1/99 (1%) | 1 | 0/87 (0%) | 1 | 4/192 (2.1%) | 4 | 1/177 (0.6%) | 1 | 14/227 (6.2%) | 15 | 16/267 (6%) | 19 | 0/97 (0%) | 19 | 0/95 (0%) | 19 | ||||
| Headache | 8/15 (53.3%) | 15 | 4/15 (26.7%) | 6 | 7/15 (46.7%) | 7 | 0/15 (0%) | 7 | 24/99 (24.2%) | 29 | 6/87 (6.9%) | 9 | 77/192 (40.1%) | 117 | 46/177 (26%) | 69 | 118/227 (52%) | 182 | 100/267 (37.5%) | 161 | 4/97 (4.1%) | 4 | 0/95 (0%) | 4 |
| Migraine | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 0/87 (0%) | 0/192 (0%) | 0/177 (0%) | 0/227 (0%) | 4/267 (1.5%) | 4 | 0/97 (0%) | 4 | 0/95 (0%) | 4 | |||||||||
| Renal and urinary disorders | ||||||||||||||||||||||||
| Cystitis | 0/15 (0%) | 0 | 0/15 (0%) | 0 | 0/15 (0%) | 0 | 0/15 (0%) | 0 | 0/99 (0%) | 0 | 0/87 (0%) | 0 | 1/192 (0.5%) | 1 | 0/177 (0%) | 1 | 0/227 (0%) | 1 | 2/267 (0.7%) | 2 | 0/97 (0%) | 2 | 0/95 (0%) | 2 |
| Urinary tract infection | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 2/15 (13.3%) | 2 | 3/99 (3%) | 3 | 2/87 (2.3%) | 2 | 3/192 (1.6%) | 4 | 2/177 (1.1%) | 2 | 2/227 (0.9%) | 2 | 5/267 (1.9%) | 5 | 0/97 (0%) | 5 | 1/95 (1.1%) | 1 | |||
| Reproductive system and breast disorders | ||||||||||||||||||||||||
| Dysmenorrhea | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 0/87 (0%) | 0/192 (0%) | 2/177 (1.1%) | 2 | 0/227 (0%) | 2 | 1/267 (0.4%) | 1 | 0/97 (0%) | 1 | 0/95 (0%) | 1 | |||||||
| Mastitis | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 0/87 (0%) | 0/192 (0%) | 1/177 (0.6%) | 1 | 1/227 (0.4%) | 1 | 3/267 (1.1%) | 3 | 0/97 (0%) | 3 | 0/95 (0%) | 3 | |||||||
| Menstrual disorder | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 0/87 (0%) | 0/192 (0%) | 0/177 (0%) | 0/227 (0%) | 1/267 (0.4%) | 1 | 0/97 (0%) | 1 | 0/95 (0%) | 1 | |||||||||
| Respiratory, thoracic and mediastinal disorders | ||||||||||||||||||||||||
| Bronchitis | 1/15 (6.7%) | 1 | 1/15 (6.7%) | 1 | 1/15 (6.7%) | 2 | 2/15 (13.3%) | 2 | 9/99 (9.1%) | 10 | 13/87 (14.9%) | 13 | 13/192 (6.8%) | 13 | 10/177 (5.6%) | 10 | 21/227 (9.3%) | 24 | 14/267 (5.2%) | 14 | 9/97 (9.3%) | 10 | 14/95 (14.7%) | 19 |
| Cough | 3/15 (20%) | 3 | 0/15 (0%) | 3 | 1/15 (6.7%) | 1 | 3/15 (20%) | 3 | 6/99 (6.1%) | 6 | 4/87 (4.6%) | 4 | 17/192 (8.9%) | 20 | 6/177 (3.4%) | 6 | 6/227 (2.6%) | 6 | 14/267 (5.2%) | 15 | 6/97 (6.2%) | 6 | 4/95 (4.2%) | 4 |
| Epistaxis | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 0/87 (0%) | 0/192 (0%) | 0/177 (0%) | 0/227 (0%) | 1/267 (0.4%) | 1 | 0/97 (0%) | 1 | 0/95 (0%) | 1 | |||||||||
| Layrngitis | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 0/87 (0%) | 0/192 (0%) | 0/177 (0%) | 0/227 (0%) | 1/267 (0.4%) | 1 | 0/97 (0%) | 1 | 0/95 (0%) | 1 | |||||||||
| Nasopharyngitis | 2/15 (13.3%) | 2 | 3/15 (20%) | 3 | 2/15 (13.3%) | 2 | 3/15 (20%) | 3 | 16/99 (16.2%) | 18 | 11/87 (12.6%) | 11 | 12/192 (6.3%) | 12 | 8/177 (4.5%) | 8 | 13/227 (5.7%) | 15 | 11/267 (4.1%) | 11 | 16/97 (16.5%) | 19 | 8/95 (8.4%) | 9 |
| Pneumonia | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 0/87 (0%) | 0/192 (0%) | 0/177 (0%) | 0/227 (0%) | 3/267 (1.1%) | 3 | 0/97 (0%) | 3 | 0/95 (0%) | 3 | |||||||||
| Rhinitis | 10/15 (66.7%) | 14 | 5/15 (33.3%) | 8 | 8/15 (53.3%) | 15 | 6/15 (40%) | 13 | 57/99 (57.6%) | 93 | 44/87 (50.6%) | 76 | 100/192 (52.1%) | 162 | 96/177 (54.2%) | 149 | 103/227 (45.4%) | 157 | 136/267 (50.9%) | 211 | 56/97 (57.7%) | 79 | 60/95 (63.2%) | 96 |
| Rhinorrhea | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 0/87 (0%) | 2/192 (1%) | 2 | 2/177 (1.1%) | 2 | 1/227 (0.4%) | 1 | 2/267 (0.7%) | 2 | 0/97 (0%) | 2 | 0/95 (0%) | 2 | ||||||
| Sinobronchitis | 1/15 (6.7%) | 1 | 0/15 (0%) | 1 | 2/15 (13.3%) | 2 | 0/15 (0%) | 2 | 10/99 (10.1%) | 10 | 3/87 (3.4%) | 4 | 7/192 (3.6%) | 8 | 10/177 (5.6%) | 11 | 9/227 (4%) | 10 | 14/267 (5.2%) | 14 | 7/97 (7.2%) | 8 | 4/95 (4.2%) | 6 |
| Skin and subcutaneous tissue disorders | ||||||||||||||||||||||||
| Arthropod sting | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 0/87 (0%) | 2/192 (1%) | 2 | 0/177 (0%) | 2 | 0/227 (0%) | 2 | 0/267 (0%) | 2 | 0/97 (0%) | 2 | 0/95 (0%) | 2 | ||||||
| Blister | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 1/99 (1%) | 1 | 0/87 (0%) | 1 | 0/192 (0%) | 1 | 1/177 (0.6%) | 1 | 0/227 (0%) | 1 | 0/267 (0%) | 1 | 0/97 (0%) | 1 | 0/95 (0%) | 1 | ||||
| Circumcision | 0/15 (0%) | 0 | 0/15 (0%) | 0 | 0/15 (0%) | 0 | 0/15 (0%) | 0 | 0/99 (0%) | 0 | 1/87 (1.1%) | 1 | 0/192 (0%) | 1 | 0/177 (0%) | 0 | 0/227 (0%) | 0 | 0/267 (0%) | 0 | 0/97 (0%) | 0 | 1/95 (1.1%) | 1 |
| Dermatosis | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 0/87 (0%) | 0/192 (0%) | 0/177 (0%) | 0/227 (0%) | 1/267 (0.4%) | 1 | 0/97 (0%) | 1 | 0/95 (0%) | 1 | |||||||||
| Erysipelas | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 0/87 (0%) | 1/192 (0.5%) | 1 | 0/177 (0%) | 1 | 0/227 (0%) | 1 | 0/267 (0%) | 1 | 0/97 (0%) | 1 | 0/95 (0%) | 1 | ||||||
| Fungal skin infection | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 0/87 (0%) | 0/192 (0%) | 0/177 (0%) | 0/227 (0%) | 1/267 (0.4%) | 1 | 0/97 (0%) | 1 | 0/95 (0%) | 1 | |||||||||
| Furuncle | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 0/87 (0%) | 1/192 (0.5%) | 1 | 3/177 (1.7%) | 3 | 3/227 (1.3%) | 3 | 0/267 (0%) | 3 | 0/97 (0%) | 3 | 0/95 (0%) | 3 | ||||||
| Injection site induration | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 0/87 (0%) | 0/192 (0%) | 0/177 (0%) | 0/227 (0%) | 2/267 (0.7%) | 2 | 0/97 (0%) | 2 | 0/95 (0%) | 2 | |||||||||
| Lip swelling | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 1/99 (1%) | 1 | 0/87 (0%) | 1 | 0/192 (0%) | 1 | 0/177 (0%) | 1 | 0/227 (0%) | 1 | 0/267 (0%) | 1 | 0/97 (0%) | 1 | 0/95 (0%) | 1 | ||||
| Prurigo | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 1/15 (6.7%) | 1 | 0/99 (0%) | 1 | 0/87 (0%) | 1 | 0/192 (0%) | 1 | 0/177 (0%) | 1 | 0/227 (0%) | 1 | 2/267 (0.7%) | 2 | 0/97 (0%) | 2 | 0/95 (0%) | 2 | |||
| Pruritis | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 0/87 (0%) | 0/192 (0%) | 0/177 (0%) | 2/227 (0.9%) | 2 | 0/267 (0%) | 2 | 0/97 (0%) | 2 | 0/95 (0%) | 2 | ||||||||
| Pyoderma | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 1/87 (1.1%) | 1 | 2/192 (1%) | 2 | 0/177 (0%) | 2 | 1/227 (0.4%) | 1 | 0/267 (0%) | 1 | 0/97 (0%) | 1 | 0/95 (0%) | 1 | |||||
| Urticaria | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 1/15 (6.7%) | 1 | 1/99 (1%) | 1 | 1/87 (1.1%) | 1 | 4/192 (2.1%) | 4 | 3/177 (1.7%) | 3 | 4/227 (1.8%) | 4 | 6/267 (2.2%) | 6 | 2/97 (2.1%) | 6 | 1/95 (1.1%) | 1 | |||
| Wound | 1/15 (6.7%) | 0/15 (0%) | 1/15 (6.7%) | 1 | 1/15 (6.7%) | 1 | 4/99 (4%) | 5 | 6/87 (6.9%) | 6 | 5/192 (2.6%) | 5 | 9/177 (5.1%) | 10 | 5/227 (2.2%) | 5 | 5/267 (1.9%) | 5 | 0/97 (0%) | 0 | 3/95 (3.2%) | 3 | ||
| Vascular disorders | ||||||||||||||||||||||||
| Arteritis | 0/15 (0%) | 0 | 0/15 (0%) | 0 | 0/15 (0%) | 0 | 0/15 (0%) | 0 | 0/99 (0%) | 0 | 0/87 (0%) | 0 | 0/192 (0%) | 0 | 0/177 (0%) | 0 | 0/227 (0%) | 0 | 1/267 (0.4%) | 1 | 0/97 (0%) | 1 | 0/95 (0%) | 1 |
| Diastolic hypertension | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 0/87 (0%) | 1/192 (0.5%) | 1 | 0/177 (0%) | 1 | 0/227 (0%) | 1 | 1/267 (0.4%) | 1 | 0/97 (0%) | 1 | 0/95 (0%) | 1 | ||||||
| Hypertension | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 0/87 (0%) | 0/192 (0%) | 0/177 (0%) | 1/227 (0.4%) | 1 | 0/267 (0%) | 1 | 0/97 (0%) | 1 | 0/95 (0%) | 1 | ||||||||
| Systolic hypertension | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/99 (0%) | 0/87 (0%) | 0/192 (0%) | 0/177 (0%) | 3/227 (1.3%) | 3 | 1/267 (0.4%) | 1 | 0/97 (0%) | 1 | 0/95 (0%) | 1 | ||||||||
Limitations/Caveats
More Information
Certain Agreements
All Principal Investigators ARE employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
| Name/Title | Patrick E. Duffy |
|---|---|
| Organization | Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health |
| Phone | 301.761.5089 |
| patrick.duffy@nih.gov |
- 999919086
- 19-I-N086